Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma (clinicaltrials.gov) - Sep 26, 2026 - P1 | N=120 | Recruiting | Sponsor: Biocon Biologics UK PLC | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Melanoma • Oncology • Solid Tumor
|